OC
TARA icon

Oppenheimer & Co’s Protara Therapeutics TARA Stock Holding History

Oppenheimer & Co’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$911K Buy
238,362
+56,797
+31% +$270K 0.01% 975
2026
Q1 		$946K Sell
181,565
-42,202
-19% -$250K 0.01% 888
2025
Q4 		$1.19M Buy
223,767
+16,794
+8% +$93.4K 0.02% 730
2025
Q3 		$900K Sell
206,973
-39,091
-16% -$127K 0.01% 948
2025
Q2 		$746K Buy
246,064
+59,500
+32% +$205K 0.01% 984
2025
Q1 		$795K Sell
186,564
-14,862
-7% -$66.4K 0.01% 899
2024
Q4 		$1.06M Buy
201,426
+22,301
+12% +$72K 0.02% 755
2024
Q3 		$328K Buy
179,125
+51,944
+41% +$107K 0.01% 1190
2024
Q2 		$265K Buy
127,181
+117,181
+1,172% +$343K ﹤0.01% 1240
2024
Q1 		$40.1K Buy
+10,000
New +$32.3K ﹤0.01% 1418

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Oppenheimer & Co's TARA Position: Q2 2026 in Review

Oppenheimer & Co increased its Protara Therapeutics (TARA) stake by 31% in Q2 2026, buying an estimated $270K and bringing the position to 238,362 shares worth $911K. The position accounts for 0.01% of the portfolio, ranked #975.

Oppenheimer & Co first reported a position in TARA in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.19M in Q4 2025. 120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Oppenheimer & Co held 238,362 shares of Protara Therapeutics worth $911K as of Q2 2026.
  • Oppenheimer & Co bought 56,797 Protara Therapeutics shares in Q2 2026, an estimated $270K.
  • Protara Therapeutics made up 0.01% of Oppenheimer & Co's portfolio in Q2 2026, its #975 holding.
  • Oppenheimer & Co first reported a position in Protara Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Oppenheimer & Co's Protara Therapeutics position peaked at $1.19M in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.